Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keita Nakanishi is active.

Publication


Featured researches published by Keita Nakanishi.


Journal of Human Genetics | 2017

Cryptic exon activation in SLC12A3 in Gitelman syndrome

Kandai Nozu; Yoshimi Nozu; Keita Nakanishi; Takao Konomoto; Tomoko Horinouchi; Akemi Shono; Naoya Morisada; Shogo Minamikawa; Tomohiko Yamamura; Junya Fujimura; Koichi Nakanishi; Takeshi Ninchoji; Hiroshi Kaito; Ichiro Morioka; Mariko Taniguchi-Ikeda; Igor Vorechovsky; Kazumoto Iijima

Gitelman syndrome (GS) is an autosomal recessive renal tubulopathy characterized by hypokalemic metabolic alkalosis with hypocalciuria and hypomagnesemia. GS clinical symptoms range from mild weakness to muscular cramps, paralysis or even sudden death as a result of cardiac arrhythmia. GS is caused by loss-of-function mutations in the solute carrier family 12 member 3 (SLC12A3) gene, but molecular mechanisms underlying such a wide range of symptoms are poorly understood. Here we report cryptic exon activation in SLC12A3 intron 12 in a clinically asymptomatic GS, resulting from an intronic mutation c.1669+297 T>G that created a new acceptor splice site. The cryptic exon was sandwiched between the L3 transposon upstream and a mammalian interspersed repeat downstream, possibly contributing to inclusion of the cryptic exon in mature transcripts. The mutation was identified by targeted next-generation sequencing of candidate genes in GS patients with missing pathogenic SLC12A3 alleles. Taken together, this work illustrates the power of next-generation sequencing to identify causal mutations in intronic regions in asymptomatic individuals at risk of developing potentially fatal disease complications, improving clinical management of these cases.


Clinical and Experimental Nephrology | 2017

Diagnostic strategy for inherited hypomagnesemia

Tomoko Horinouchi; Kandai Nozu; Naohiro Kamiyoshi; Koichi Kamei; Hiroko Togawa; Yuko Shima; Yoshimichi Urahama; Tomohiko Yamamura; Shogo Minamikawa; Keita Nakanishi; Junya Fujimura; Ichiro Morioka; Takeshi Ninchoji; Hiroshi Kaito; Koichi Nakanishi; Kazumoto Iijima

BackgroundHereditary hypomagnesemia is difficult to diagnose accurately because of its rarity and the variety of causative genes. We established a flowchart for identifying responsible genes for hypomagnesemia, and we confirmed its diagnostic efficacy in patients with suspected inherited hypomagnesemia.MethodsWe established a flowchart and applied it to five index cases with suspected inherited hypomagnesemia. Direct sequence analysis was used to detect the causative gene variants in four cases, and targeted sequencing analysis using next-generation sequencing (NGS) of all causative genes for hypomagnesemia was used in one.ResultsExpected pathogenic variants were detected in the HNF1B, TRPM6, CLDN16, CASR, or SLC12A3 gene in all five cases. The results of all genetic analyses were consistent with the clinical diagnostic results using the flowchart.ConclusionsAccurate genetic diagnosis is crucial for estimating the prognosis, detecting complications in organs other than the kidneys, and for directing genetic counseling. The developed flowchart for identifying responsible genes for hypomagnesemia was useful for diagnosing inherited hypomagnesemia. In addition, NGS analysis will help to resolve clinical difficulties in making an accurate diagnosis and thus improve the diagnostic strategy for inherited hypomagnesemia.


Journal of The American Society of Nephrology | 2018

Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome

Tomoko Horinouchi; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Takashi Omori; Keita Nakanishi; Junya Fujimura; Akira Ashida; Mineaki Kitamura; Mitsuhiro Kawano; Wataru Shimabukuro; Chizuko Kitabayashi; Aya Imafuku; Keiichi Tamagaki; Koichi Kamei; Kenjirou Okamoto; Shuichiro Fujinaga; Masafumi Oka; Toru Igarashi; Akinori Miyazono; Emi Sawanobori; Rika Fujimaru; Koichi Nakanishi; Yuko Shima; Masafumi Matsuo; Ming Juan Ye; Yoshimi Nozu; Naoya Morisada; Hiroshi Kaito; Kazumoto Iijima

BACKGROUND X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the COL4A5 gene. Genotype-phenotype correlation in male XLAS is relatively well established; relative to truncating mutations, nontruncating mutations exhibit milder phenotypes. However, transcript comparison between XLAS cases with splicing abnormalities that result in a premature stop codon and those with nontruncating splicing abnormalities has not been reported, mainly because transcript analysis is not routinely conducted in patients with XLAS. METHODS We examined transcript expression for all patients with suspected splicing abnormalities who were treated at one hospital between January of 2006 and July of 2017. Additionally, we recruited 46 males from 29 families with splicing abnormalities to examine genotype-phenotype correlation in patients with truncating (n=21, from 14 families) and nontruncating (n=25, from 15 families) mutations at the transcript level. RESULTS We detected 41 XLAS families with abnormal splicing patterns and described novel XLAS atypical splicing patterns (n=14) other than exon skipping caused by point mutations in the splice consensus sequence. The median age for developing ESRD was 20 years (95% confidence interval, 14 to 23 years) among patients with truncating mutations and 29 years (95% confidence interval, 25 to 40 years) among patients with nontruncating mutations (P=0.001). CONCLUSIONS We report unpredictable atypical splicing in the COL4A5 gene in male patients with XLAS and reveal that renal prognosis differs significantly for patients with truncating versus nontruncating splicing abnormalities. Our results suggest that splicing modulation should be explored as a therapy for XLAS with truncating mutations.


Clinical and Experimental Nephrology | 2018

Detection of copy number variations by pair analysis using next-generation sequencing data in inherited kidney diseases

China Nagano; Kandai Nozu; Naoya Morisada; Masahiko Yazawa; Daisuke Ichikawa; Keita Numasawa; Hiroyo Kourakata; Chieko Matsumura; Satoshi Tazoe; Ryojiro Tanaka; Tomohiko Yamamura; Shogo Minamikawa; Tomoko Horinouchi; Keita Nakanishi; Junya Fujimura; Nana Sakakibara; Yoshimi Nozu; Ming Juan Ye; Hiroshi Kaito; Kazumoto Iijima

BackgroundComprehensive genetic approaches for diagnosing inherited kidney diseases using next-generation sequencing (NGS) have recently been established. However, even with these approaches, we are still failing to detect gene defects in some patients who appear to suffer from genetic diseases. One of the reasons for this is the difficulty of detecting copy number variations (CNVs) using our current approaches. For such cases, we can apply methods of array-based comparative genomic hybridization (aCGH) or multiplex ligation and probe amplification (MLPA); however, these are expensive and laborious and also often fail to identify CNVs. Here, we report seven cases with CNVs in various inherited kidney diseases screened by NGS pair analysis.MethodsTargeted sequencing analysis for causative genes was conducted for cases with suspected inherited kidney diseases, for some of which a definitive genetic diagnosis had not been achieved. We conducted pair analysis using NGS data for those cases. When CNVs were detected by pair analysis, they were confirmed by aCGH and/or MLPA.ResultsIn seven cases, CNVs in various causative genes of inherited kidney diseases were detected by pair analysis. With aCGH and/or MLPA, pathogenic CNV variants were confirmed: COL4A5 or HNF1B in two cases each, and EYA1, CLCNKB, or PAX2 in one each.ConclusionWe presented seven cases with CNVs in various genes that were screened by pair analysis. The NGS-based CNV detection method is useful for comprehensive screening of CNVs, and our results revealed that, for a certain proportion of cases, CNV analysis is necessary for accurate genetic diagnosis.


Nephron | 2018

Detection of a Splice Site Variant in a Patient with Glomerulopathy and Fibronectin Deposits

Yurika Tsuji; Kandai Nozu; Tadashi Sofue; Shigeo Hara; Keita Nakanishi; Tomohiko Yamamura; Shogo Minamikawa; Yoshimi Nozu; Hiroshi Kaito; Junya Fujimura; Tomoko Horinouchi; Naoya Morisada; Ichiro Morioka; Mariko Taniguchi-Ikeda; Masafumi Matsuo; Kazumoto Iijima

Background/Aims: Glomerulopathy with fibronectin deposits (GFND; OMIM: 601894) is a very rare inherited kidney disease caused by pathogenic variants in the FN1 gene. Only 9 exonic pathogenic variants in FN1, 9 at the heparin-binding site, and 1 at the integrin-binding site have been reported. No intronic variants in FN1 have been detected. Methods: We found a pathogenic intronic variant in intron 36 (c.5888–2A>G) located at the heparin-binding site. To determine whether this mutation influences splicing processes, we conducted RT-PCR analysis and an in vitro splicing assay using minigene construction. Results: RT-PCR using RNA extracted from leukocytes of the proband failed because of the low expression of FN1 mRNA in leukocytes. We conducted in vitro functional splicing analysis using minigenes and found that c.5888–2A>G caused a 12 bp deletion at exon 37 by the activation of a novel splicing acceptor site within exon 37. We were able to detect the same abnormal transcript in mRNA extracted from the patient’s urinary sediment and confirmed the pathogenicity of c.5888–2A>G by both RT-PCR using the patient sample and an in vitro splicing assay. Conclusion: Intronic variants can cause GFND. Minigene analysis is useful for determining the pathogenicity of the intronic variants and could be used for all inherited kidney diseases.


Kidney International Reports | 2018

Clinical and Genetic Characteristics in Patients With Gitelman Syndrome

Junya Fujimura; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Keita Nakanishi; Tomoko Horinouchi; China Nagano; Nana Sakakibara; Koichi Nakanishi; Yuko Shima; Kenichi Miyako; Yoshimi Nozu; Naoya Morisada; Hiroaki Nagase; Takeshi Ninchoji; Hiroshi Kaito; Kazumoto Iijima

Introduction Gitelman syndrome (GS) is a tubulopathy exhibited by salt loss. GS cases are most often diagnosed by chance blood test. Aside from that, some cases are also diagnosed from tetanic symptoms associated with hypokalemia and/or hypomagnesemia or short stature. As for complications, thyroid dysfunction and short stature are known, but the incidence rates for these complications have not yet been elucidated. In addition, no genotype–phenotype correlation has been identified in GS. Methods We examined the clinical characteristics and genotype–phenotype correlation in genetically proven GS cases with homozygous or compound heterozygous variants in SLC12A3 (n = 185). Results In our cohort, diagnostic opportunities were by chance blood tests (54.7%), tetany (32.6%), or short stature (7.2%). Regarding complications, 16.3% had short stature, 13.7% had experienced febrile convulsion, 4.3% had thyroid dysfunction, and 2.5% were diagnosed with epilepsy. In one case, QT prolongation was detected. Among 29 cases with short stature, 10 were diagnosed with growth hormone (GH) deficiency and GH replacement therapy started. Interestingly, there was a strong correlation in serum magnesium levels between cases with p.Arg642Cys and/or p.Leu858His and cases without these variants, which are mutational hotspots in the Japanese population (1.76 mg/dl vs. 1.43 mg/dl, P < 0.001). Conclusion This study has revealed, for the first time, clinical characteristics in genetically proven GS cases in the Japanese population, including prevalence of complications. Patients with hypokalemia detected by chance blood test should have gene tests performed. Patients with GS need attention for developing extrarenal complications, such as short stature, febrile convulsion, thyroid dysfunction, epilepsy, or QT prolongation. It was also revealed for the first time that hypomagnesemia was not severe in some variants in SLC12A3.


Journal of International Medical Research | 2018

Clinical features predicting group A streptococcal pharyngitis in a Japanese paediatric primary emergency medical centre

Masahiro Nishiyama; Ichiro Morioka; Mariko Taniguchi-Ikeda; Takeshi Mori; Kazumi Tomioka; Keita Nakanishi; Junya Fujimura; Noriyuki Nishimura; Kandai Nozu; Hiroaki Nagase; Kazuto Ishibashi; Akihito Ishida; Kazumoto Iijima

Objectives To identify clinical features that predict Group A streptococcal (GAS) pharyngitis in a Japanese paediatric primary emergency medical centre. Methods The prevalence of GAS pharyngitis according to age and body temperature (BT) was calculated among 3098 paediatric patients with pharyngitis. The numbers of GAS-positive and -negative patients for each clinical parameter, and each point increase in the McIsaac score were compared and likelihood ratios (LRs) were calculated. Results The prevalence of GAS pharyngitis was extremely low in patients aged < 1 (1.2%) and 1 year (3.9%). The GAS-positive rate was significantly higher in patients with a BT < 38.0°C compared with ≥ 38.0°C (30.0% vs. 19.8%). A BT ≥ 38.0°C was not a predictive finding for GAS pharyngitis (positive LR: 0.82). Rash was the most useful individual predictor, and a McIsaac score of 4 or 5 increased the probability; however, the positive LRs were 1.74 and 1.30, respectively. Conclusions The prevalence of GAS pharyngitis is extremely low in patients aged < 1 and 1 year, and a BT ≥ 38.0°C is not a predictive symptom. Although a rash and McIsaac score of 4 or 5 are associated with an increased probability, they cannot be used to confirm GAS infection.


Journal of Human Genetics | 2018

Development of ultra-deep targeted RNA sequencing for analyzing X-chromosome inactivation in female Dent disease

Shogo Minamikawa; Kandai Nozu; Yoshimi Nozu; Tomohiko Yamamura; Mariko Taniguchi-Ikeda; Keita Nakanishi; Junya Fujimura; Tomoko Horinouchi; Yuko Shima; Koichi Nakanishi; Masuji Hattori; Kyoko Kanda; Ryojiro Tanaka; Naoya Morisada; China Nagano; Nana Sakakibara; Hiroaki Nagase; Ichiro Morioka; Hiroshi Kaito; Kazumoto Iijima

The pattern of X-chromosome inactivation (XCI) can affect the clinical severity of X-linked disorders in females. XCI pattern analysis has been conducted mainly by HUMARA assay, a polymerase chain reaction-based assay using a methylation-sensitive restriction enzyme. However, this assay examines the XCI ratio of the androgen receptor gene at the genomic DNA level and does not reflect the ratio of either targeted gene directly or at the mRNA level. Here, we report four females with Dent disease, and we clarified the correlation between XCI and female cases of Dent disease using not only HUMARA assay but also a novel analytical method by RNA sequencing. We constructed genetic analysis for 4 female cases showing high level of urinary low-molecular-weight proteinuria and their parents. Their XCI pattern was analyzed by both HUMARA assay and an ultra-deep targeted RNA sequencing of the CLCN5 gene using genomic DNA and mRNA extracted from both leukocytes and urine sediment. All four cases possessed pathogenic variants of the CLCN5 gene. XCI analysis revealed skewed XCI in only two cases, while the other two showed random XCI. All assay results of HUMARA and targeted RNA sequencing in both leukocytes and urinary sediment were clearly identical in all four cases. We developed a novel XCI analytical assay of ultra-deep targeted RNA sequencing and revealed that skewed XCI explains the mechanism of onset of female Dent disease in only half of such cases.


Journal of Human Genetics | 2018

Congenital chloride diarrhea needs to be distinguished from Bartter and Gitelman syndrome

Natsuki Matsunoshita; Kandai Nozu; Masahide Yoshikane; Azusa Kawaguchi; Naoya Fujita; Naoya Morisada; Shingo Ishimori; Tomohiko Yamamura; Shogo Minamikawa; Tomoko Horinouchi; Keita Nakanishi; Junya Fujimura; Takeshi Ninchoji; Ichiro Morioka; Hiroaki Nagase; Mariko Taniguchi-Ikeda; Hiroshi Kaito; Kazumoto Iijima

Pseudo-Bartter/Gitelman syndrome (p-BS/GS) encompasses a clinically heterogeneous group of inherited or acquired disorders similar to Bartter syndrome (BS) or Gitelman syndrome (GS), both renal salt-losing tubulopathies. Phenotypic overlap frequently occurs between p-BS/GS and BS/GS, which are difficult to diagnose based on their clinical presentation and require genetic tests for accurate diagnosis. In addition, p-BS/GS can occur as a result of other inherited diseases such as cystic fibrosis, autosomal dominant hypocalcemia, Dent disease, or congenital chloride diarrhea (CCD). However, the detection of the variants in genes other than known BS/GS-causing genes by conventional Sanger sequencing requires substantial time and resources. We studied 27 cases clinically diagnosed with BS/GS, but with negative genetic tests for known BS/GS genes. We conducted targeted sequencing for 22 genes including genes responsible for tubulopathies and other inherited diseases manifesting with p-BS/GS symptoms. We detected the SLC26A3 gene variants responsible for CCD in two patients. In Patient 1, we found the SLC26A3 compound heterozygous variants: c.354delC and c.1008insT. In Patient 2, we identified the compound heterozygous variants: c.877G > A, p.(Glu293Lys), and c.1008insT. Our results suggest that a comprehensive genetic screening system using targeted sequencing is useful for the diagnosis of patients with p-BS/GS with alternative genetic origins.


Case reports in nephrology | 2018

Three Severe Cases of Viral Infections with Post-Kidney Transplantation Successfully Confirmed by Polymerase Chain Reaction and Flow Cytometry

Keita Nakanishi; Hiroshi Kaito; Miki Ogi; Denshi Takai; Junya Fujimura; Tomoko Horinouchi; Tomohiko Yamamura; Shogo Minamikawa; Takeshi Ninchoji; Kandai Nozu; Ken-Ichi Imadome; Kazumoto Iijima

Viral infections in patients with post-kidney transplantation are often difficult to diagnose as well as treat. We herein report three cases with severe viral infections after kidney transplantation. All their causative pathogens could be detected promptly by polymerase chain reaction and flow cytometry during the early stages of infection. These examinations would also be of great use to monitor therapeutic responses and disease activity. It is indeed true that no specific treatment is available for most of the viral infections, but we should be aware that some infections, such as Epstein-Barr virus infection, can be treatable with prompt and specific treatment, such as rituximab.

Collaboration


Dive into the Keita Nakanishi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge